Amneal Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(unaudited; in thousands, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net revenue | $724,508 | $701,780 | $1,419,928 | $1,360,971 |
| Cost of goods sold | 438,255 | 451,833 | 877,784 | 872,964 |
| Gross profit | 286,253 | 249,947 | 542,144 | 488,007 |
| Selling, general and administrative | 124,266 | 116,462 | 242,554 | 229,057 |
| Research and development | 47,964 | 36,054 | 88,004 | 75,352 |
| Intellectual property legal development expenses | 2,017 | 1,042 | 3,784 | 2,026 |
| Restructuring and other charges | 1,024 | 220 | 1,595 | 1,690 |
| (Credit) charges related to legal matters, net | (390) | 699 | (390) | 95,058 |
| Other operating (income) expense | — | — | (5,122) | 100 |
| Operating income | 111,372 | 95,470 | 211,719 | 84,724 |
| Other (expense) income: | ||||
| Interest expense, net | (65,101) | (65,719) | (122,040) | (131,422) |
| Foreign exchange gain (loss), net | 8,256 | (262) | 12,503 | (1,459) |
| Increase in tax receivable agreement liability | (4,420) | (13,444) | (15,107) | (15,392) |
| Other income, net | 1,604 | 4,360 | 2,122 | 8,432 |
| Total other expense, net | (59,661) | (75,065) | (122,522) | (139,841) |
| Income (loss) before income taxes | 51,711 | 20,405 | 89,197 | (55,117) |
| Provision for income taxes | 16,101 | 3,618 | 28,969 | 9,774 |
| Net income (loss) | 35,610 | 16,787 | 60,228 | (64,891) |
| Less: Net income attributable to non-controlling interests | (13,193) | (10,793) | (25,616) | (20,758) |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | $22,417 | $5,994 | $34,612 | $(85,649) |
| Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: | ||||
| Basic | $0.07 | $0.02 | $0.11 | $(0.28) |
| Diluted | $0.07 | $0.02 | $0.11 | $(0.28) |
| Weighted-average common shares outstanding: | ||||
| Basic | 313,739 | 309,117 | 312,404 | 308,198 |
| Diluted | 322,363 | 318,957 | 323,171 | 308,198 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.